{"id":"NCT03783078","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)","officialTitle":"A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-25","primaryCompletion":"2022-02-15","completion":"2024-02-15","firstPosted":"2018-12-20","resultsPosted":"2023-02-17","lastUpdate":"2025-05-28"},"enrollment":55,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Merkel Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Pembrolizumab (MK-3475)","otherNames":["MK-3475"]}],"arms":[{"label":"Pembrolizumab","type":"EXPERIMENTAL"}],"summary":"This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.","primaryOutcome":{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to ~34 months","effectByArm":[{"arm":"Pembrolizumab 200 mg","deltaMin":49.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":20},"locations":{"siteCount":22,"countries":["United States","Australia","Canada","France","Italy","New Zealand","Spain","Sweden"]},"refs":{"pmids":["39377880"],"seeAlso":["https://www.merckclinicaltrials.com","https://www.trialsummaries.com/Study/StudyDetails?id=26661&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":55},"commonTop":["Fatigue","Pruritus","Aspartate aminotransferase increased","Asthenia","Alanine aminotransferase increased"]}}